COWEALTH MEDICAL CHINA CO.,LTD. Cowealth Medical China Co.,Ltd. Stock
Equities
603122
CNE100005R39
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.51 CNY | +1.56% |
|
+3.83% | -19.13% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.28B 177M 244M | Sales 2023 | 1.09B 151M 208M | Capitalization | 3.2B 444M 610M |
|---|---|---|---|---|---|
| Net income 2022 | 82M 11.35M 15.61M | Net income 2023 | 47M 6.51M 8.95M | EV / Sales 2022 | 3.28 x |
| Net cash position 2022 | 257M 35.55M 48.9M | Net cash position 2023 | 127M 17.57M 24.17M | EV / Sales 2023 | 2.82 x |
| P/E ratio 2022 |
50.9
x | P/E ratio 2023 |
67.1
x | Employees | 240 |
| Yield 2022 |
1.34% | Yield 2023 |
0.75% | Free-Float | 40.92% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.56% | ||
| 1 week | +3.83% | ||
| Current month | +3.83% | ||
| 1 month | -4.96% | ||
| 3 months | +22.60% | ||
| 6 months | -22.32% | ||
| Current year | -19.13% |
1 week
6.30
6.51
1 month
5.596.75
Current year
5.208.40
1 year
5.2011.30
3 years
5.0327.27
5 years
5.0327.27
10 years
5.0327.27
| Managers | Title | Age | Since |
|---|---|---|---|
Qiong Zhi Wang
CEO | Chief Executive Officer | 67 | 00-06-30 |
Duane Lee
CHM | Chairman | 68 | 00-09-30 |
Xiao Jun Yang
BRD | Director/Board Member | 38 | 10-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qiong Zhi Wang
CEO | Chief Executive Officer | 67 | 00-06-30 |
Duane Lee
CHM | Chairman | 68 | 00-09-30 |
Yi Chang
BRD | Director/Board Member | 66 | 19-03-21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 6.51 | +1.56% | 5,575,000 |
| 24-05-06 | 6.41 | +2.23% | 4,769,598 |
| 24-04-30 | 6.27 | +0.32% | 5,365,400 |
End-of-day quote Shanghai S.E., May 06, 2024
More quotes
Cowealth Medical China Co Ltd is a China-based company mainly engaged in the wholesale of medical equipment products. The Company's businesses include in-vitro diagnostic product intensive business and medical product distribution business. The in-vitro diagnostic product intensive business is engaged in the wholesale business of in vitro diagnostic products, mainly including immunodiagnosis, biochemical diagnosis, clinical testing, real-time testing, molecular diagnosis, pathology, microbiological testing, blood source safety monitoring and others. The medical product distribution business mainly includes the wholesale sales of equipment in the field of swelling, immunodiagnosis and biochemical diagnosis. The Company mainly operates its business in the domestic market.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -19.13% | 359M | |
| -5.96% | 9.15B | |
| -1.87% | 1.45B | |
| -2.91% | 1.43B | |
| -6.98% | 1.22B | |
| -12.73% | 919M | |
| 0.00% | 480M | |
| +4.41% | 444M | |
| -48.94% | 369M | |
| -2.93% | 215M |
- Stock Market
- Equities
- 603122 Stock